In this issue, Rubinson, Tanaka, and colleagues demonstrate that differences among G12C inhibitors rely on their ability to covalently bind not only G12C mutant KRAS but also NRAS and HRAS, proposing sotorasib as a potent NRAS G12C inhibitor. See related article by Rubinson et al., p. 727 (6).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1158/2159-8290.CD-24-0175 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!